Valneva SE (VALN)
VALNNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$5.57
-0.1650 (-2.88%) today
Closed, Nov 17, 4:00 PM ET
- Market cap
- $536.10m
- P/E
- –
- EPS, last 4 quarters
- $-2.11
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.75 to $12.18
- Average volume
- –
- Previous close
- $5.73
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $18.00, +223.5% from here
Earnings
next estimate $-0.2300Next report Nov 24, 2026
Sep 2025
-103.3%
Dec 2025
-223.8%
Mar 2026
-100.0%
Jun 2026
-42.9%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ RTTNews · Nov 10, 2026
- Valneva Reports Positive Mid-Stage Results For Shigella Vaccine Candidate S4V2 RTTNews · Nov 9, 2026
- UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide RTTNews · Oct 8, 2026
- Why Pfizer Stock Was so Healthy in AugustThe Motley Fool · Sep 8, 2026
- Valneva (VALN) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 20, 2026
- Pfizer And Valneva's Lyme Vaccine Clears EMA Review Gate RTTNews · Aug 14, 2026
- Pfizer, Valneva's Lyme Disease Vaccine Application Validated By EMA RTTNews · Aug 14, 2026
- Valneva Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026
The company
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate under regulatory review, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- valneva.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.